In a recent interview with Fierce, Fosun Pharma co-president, Xinli Wang, M.D., Ph.D., detailed how the company leveraged two recent deals to quickly build up its portfolio in Alzheimer’s disease as part of a multi-step roadmap to establish its independent capabilities in the U.S.
- Home |
- Fosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategy
Fosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategy
- June 25, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
